🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06923254
Starting soon Observational

7.0T Magnetic Resonance Imaging Study for Hepatic Encephalopathy

NCT06923254 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Observational
Started
2025-04-03
Last updated
2025-04-11

Condition(s) studied

Hepatic Encephalopathy (HE)MRIfMRI Research

Investigational drug(s) / intervention(s)

7.0T MRI-Scan

7.0T MRI-Scan: 7.0T MRI-Scan

Study summary

This clinical trial study aims to detect the imaging characteristics of patients with hepatic encephalopathy (HE) using 7-Tesla (7T) magnetic resonance imaging (MRI).

Eligibility

Sex
ALL
Min age
18 Years
Max age
89 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with clinical suspected or diagnosed hepatic encephalopathy according to relevant guidelines.The patient's education level is above primary school level. * Regular follow-up. Exclusion Criteria: * Contraindications to MRI. * Patients with cerebrovascular disease, brain tumors, epilepsy, other neurodegenerative disease.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hospital Beijing Beijing Municipality

More Chinese PLA General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06923254 on ClinicalTrials.gov ↗ ← All trials in China